Financing Drugs in South-East Asia - Report of the First Meeting of the WHO/SEARO Working Group on Drug Financing, Korat, Thailand, 26-28 November 1996 - Health Economics and Drugs Series No. 004
(1997; 72 pages) View the PDF document
Table of Contents
Open this folder and view contentsExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Country presentations on drug financing
Open this folder and view contents3. Korat provincial field visit
Open this folder and view contents4. Drug financing issues
Open this folder and view contents5. Country priorities for drug financing
Close this folder6. Priorities for work group action
View the document6.1 Group A
View the document6.2 Group B
Open this folder and view contents7. Conclusions and recommendations
View the documentAnnex A. Agenda
View the documentAnnex B. List of participants
View the documentAnnex C. List of documents
View the documentAnnex D. Message from Regional Director, WHO South-East Asia Region
Open this folder and view contentsAnnex E. Evaluation of the meeting. Priorities for the Working Group
 

6.2 Group B

Issue 1: How to formulate policy and guidance for cost-sharing schemes (INO, MMR, NEP, THA).

Strategies:

a) WHO should provide advice on policy as well as law and/or regulations for cost-sharing scheme(s) to countries that decide to implement this type of programme.

b) Country situation studies should be made to formulate suitable policy and guidance for cost-sharing schemes.

Issue 2: How to control drug prices on the open market (THA).

Strategies:

a) Government should formulate appropriate drug pricing policy to ensure access to essential drugs.

b) Price lists should be displayed in medical shops as should information for the general public about the price of the drugs promoted.

c) The use of generic drugs should be promoted.

d) Some countries may consider providing incentives for local drug manufacturers to reduce the prices of essential drugs.

Issue 3: How to re-supply health services and get quality drugs at the lowest possible prices (MMR, NEP).

Strategies:

a) There should be a good management information system.
b) There should be good inventory control and transportation systems.
c) Producers and suppliers should have to be prequalified.
d) There should be competitive group bidding and bargaining among prequalified suppliers.

 

to previous section to next section
 

Last updated: May 3, 2013